Bank of America Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its price target increased by Bank of America from $211.00 to $213.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective would indicate a potential upside of 47.94% from the stock’s previous close.

Several other research analysts also recently commented on the company. UBS Group reduced their price objective on Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a report on Tuesday, January 6th. Roth Mkm upgraded Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Guggenheim dropped their price target on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. HC Wainwright restated a “buy” rating and set a $230.00 price target on shares of Insmed in a research note on Monday, February 23rd. Finally, Stifel Nicolaus set a $205.00 price objective on Insmed in a report on Thursday, February 19th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $204.48.

Insmed Price Performance

Shares of INSM stock opened at $143.98 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The company has a market capitalization of $31.03 billion, a P/E ratio of -22.46 and a beta of 1.13. The company’s 50-day simple moving average is $151.48 and its two-hundred day simple moving average is $166.27. Insmed has a one year low of $60.40 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. The business’s revenue was up 152.6% compared to the same quarter last year. During the same period last year, the business posted ($1.32) earnings per share. As a group, equities analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insiders Place Their Bets

In other Insmed news, CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48. Following the completion of the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,226,071.20. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Roger Adsett sold 791 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the sale, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. This represents a 0.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 189,651 shares of company stock worth $31,533,654 over the last quarter. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC grew its position in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC purchased a new position in shares of Insmed in the fourth quarter worth $27,000. Stone House Investment Management LLC acquired a new stake in shares of Insmed during the third quarter worth $29,000. SBI Securities Co. Ltd. lifted its stake in shares of Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the period. Finally, GraniteShares Advisors LLC purchased a new stake in shares of Insmed during the fourth quarter valued at $30,000.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Topline Phase 3b ENCORE results met primary and multiplicity‑controlled secondary endpoints and demonstrated improved respiratory symptoms and culture conversion; company plans an sNDA filing in H2 2026 and submission to PMDA, supporting a meaningful label expansion and addressable-market upside. PR Newswire: ENCORE topline results
• Positive Sentiment: Multiple media reports and analysts call the data a clear win that sets up a significant label expansion for ARIKAYCE and point to a larger market opportunity, driving intraday buying. FiercePharma: Label expansion story
• Positive Sentiment: Investor/analyst call transcript provides management commentary on the trial, regulatory timing and commercialization plans — useful for gauging next milestones and potential revenue impact. Seeking Alpha: Call transcript
• Neutral Sentiment: Wells Fargo lowered its price target from $208 to $175 but kept an overweight rating — trims upside but maintains a bullish view on longer-term prospects. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Broad coverage (CNBC, MarketWatch, Investing, Stat, Proactive) amplified the news and helped drive trading volume and the intraday move; market reaction reflects near-term sentiment around the ENCORE readout. CNBC: Market reaction
• Negative Sentiment: Insider activity: the CEO sold about $1.54M of stock recently, which some investors may view as a negative signal despite the positive trial news. American Banking News: Insider selling

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.